Jul 30, 2024 / 11:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Ajanta Pharma Q1 FY 2024 earning conference call.(Operator Instructions)
Please note that this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, Sir.
Yogesh Agrawal - Ajanta Pharma Ltd - Managing Director, Executive Director
Thank you. Good evening, and welcome to all of you. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO; and Mr. Rajeev Agarwal, our AVP, Finance and Investor Relations. I hope that the results are already with you by now. We will take you through business-wise performance for the Q1 of the current year along with the comparison of the previous year same period.
FY 2025 started on a good note for Ajanta Pharma with notable achievements in first quarter sales, PAT, and EBITDA. Branded generics business saw a healthy growth of 17% on the back of our strategic approach and focused execution. Our consistent efforts yielded
Q1 2025 Ajanta Pharma Ltd Earnings Call Transcript
Jul 30, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers